Logotype for Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals (ARWR) Q4 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Arrowhead Pharmaceuticals Inc

Q4 2026 earnings summary

13 Nov, 2026

Executive summary

  • FY26 marked a shift toward commercialization, led by REDEMPLO’s FCS launch and preparation for a potential SHTG launch in Q2 2027, subject to FDA approval.

  • Pipeline advances included pivotal SHTG results, dual-target RNAi data from ARO-DIMER-PA, and initial evidence of subcutaneous RNAi delivery to the CNS with ARO-MAPT.

  • Management’s priorities include growing REDEMPLO’s reach, expanding RNAi across tissues and targets, and building infrastructure to support multiple products.

Financial highlights

  • FY26 revenue was $450.817M versus $829.448M in FY25; FY26 included $317M from Sarepta, $89M from Novartis, $25M from Madrigal, $13.3M from Sanofi, and ~$6.6M of REDEMPLO net product revenue.

  • FY26 net loss was $724.206M, or $5.11 per share, versus $1.631M, or $0.01 per share, in FY25; excluding the $215M one-time PRV expense, FY26 net loss would have been ~$509M.

  • FY26 operating expenses were $1,157.988M versus $731M in FY25; excluding the PRV expense, expenses were ~$943M, up $212M year over year.

  • FY26 R&D was $739.144M versus $607.159M, and SG&A was $202.045M versus $123.943M; higher SG&A primarily reflected REDEMPLO commercialization investment.

Outlook and guidance

  • Potential U.S. SHTG launch targeted for Q2 2027, subject to FDA review and approval; the plozasiran sNDA was submitted November 2 and entered the STAR review pilot.

  • No SHTG revenue guidance yet; visibility depends on the FDA label, PDUFA timing, and payer experience. Early launch indicators include new-to-brand prescriptions, distinct prescribers, and covered lives.

  • Management sees potential for REDEMPLO to generate $3B–$4B in annual U.S. SHTG sales over time; the initial high-risk target population is nearly 1M U.S. patients.

  • Planned milestones include additional obesity data by year-end 2026, ARO-DIMER-PA data in H1 2027, YOSEMITE data in H2 2027, and initial ARO-MAPT patient data in H2 2027.

  • YOSEMITE zodasiran Phase 3 is expected to complete in mid-2027; regulatory filings in multiple geographies are planned subject to successful results.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Arrowhead Pharmaceuticals